Show simple item record

dc.contributor.authorMooranian, Armin
dc.contributor.authorNegrulj, Rebecca
dc.contributor.authorChen-Tan, Nigel
dc.contributor.authorAl-Sallami, H.
dc.contributor.authorFang, Zhongxiang
dc.contributor.authorMukkur, Trilochan
dc.contributor.authorMikov, Momir
dc.contributor.authorGolocorbin-Kon, S.
dc.contributor.authorFakhoury, M.
dc.contributor.authorArfuso, Frank
dc.contributor.authorAl-Salami, Hani
dc.identifier.citationMooranian, A. and Negrulj, R. and Chen-Tan, N. and Al-Sallami, H. and Fang, Z. and Mukkur, T. and Mikov, M. et al. 2014. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study. Drug Design, Development and Therapy. (8): pp. 1003-1012.

Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes. It has extrapancreatic hypoglycemic effects, which makes it a good candidate in type 1 diabetes (T1D). In previous studies, we have shown that a gliclazide-bile acid mixture exerted a hypoglycemic effect in a rat model of T1D. We have also shown that a gliclazide-deoxycholic acid (G-DCA) mixture resulted in better G permeation in vivo, but did not produce a hypoglycemic effect. In this study, we aimed to develop a novel microencapsulated formulation of G-DCA with uniform structure, which has the potential to enhance G pharmacokinetic and pharmacodynamic effects in our rat model of T1D. We also aimed to examine the effect that DCA will have when formulated with our new G microcapsules, in terms of morphology, structure, and excipients’ compatibility. Microencapsulation was carried out using the Büchi-based microencapsulating system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations were prepared: G-SA (control) at a ratio of 1:30, and G-DCA-SA (test) at a ratio of 1:3:30. Complete characterization of microcapsules was carried out. The new G-DCA-SA formulation was further optimized by the addition of DCA, exhibiting pseudoplastic-thixotropic rheological characteristics. The size of microcapsules remained similar after DCA addition, and these microcapsules showed no chemical interactions between the excipients. This was supported further by the spectral and microscopy studies, suggesting microcapsule stability. The new microencapsulated formulation has good structural properties and may be useful for the oral delivery of G in T1D.

dc.publisherDove Medical Press Ltd.
dc.subjecttype 2 diabetes
dc.subjectbile acids
dc.titleNovel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
dc.typeJournal Article
dcterms.source.titleDrug Design, Development and Therapy

This article is published under the Open Access publishing model and distributed under the terms of the Creative Commons License Please refer to the licence to obtain terms for any further reuse or distribution of this work

curtin.departmentSchool of Pharmacy
curtin.accessStatusOpen access

Files in this item


This item appears in the following Collection(s)

Show simple item record